Novo Holdings saw its assets shrink by a third last year as part of the fallout of Novo Nordisk’s nosediving share price. | ...

Regenxbio has guided its Duchenne muscular dystrophy (DMD) gene therapy candidate through another test, reporting a clean ...

As pharmas like Eli Lilly and Roche bolster their biotech offerings, Pfizer is snuffing out its program designed to incubate new innovations from select companies, dubbed Pfizer Ignite. | As pharmas ...

Vistagen Therapeutics is doubling down on its lead social anxiety candidate, even after the asset failed a phase 3 trial last December. | Vistagen Therapeutics is doubling down on its lead social ...

Three of the top diabetes tech companies put forward new clinical data this week, making the case for their continuous glucose monitors and insulin pumps as they look to expand their reac | Three ...

French biotech Enodia Therapeutics is paying $1 million upfront in a backloaded deal for Kezar Life Sciences’ preclinical protein degradation program. | French biotech Enodia Therapeutics is paying $1 ...

An Ultragenyx gene therapy has scored a win at the midway point of its phase 3 trial, successfully reducing ammonia levels in patients with a rare urea cycle disorder.

BridgeBio Pharma has taken another step toward the potential approval of its muscle weakness drug candidate BBP-418, ...

“Strategic transformations are a common and often successful approach in biotechnology,” Rami Levin, who took over as CEO of ...

According to a report from Bloomberg, the pro-Iran group Handala has publicly taken credit for the incident on social media, in response to the U.S. and Israeli strikes on the country, with claims of ...

A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way ...

BD has inked a technological partnership with automation provider Sinteco, aimed at pharmacy robotics. | The goal is to ...